Resumo

URINA, Miguel A; ROJAS, Catalina  e  URINA, Daniela. Cardiovascular effects of fingolimod in the treatment of multiple sclerosis. Rev. Colomb. Cardiol. [online]. 2013, vol.20, n.3, pp.149-153. ISSN 0120-5633.

Fingolimod is a disease modifying drug for patients with relapse remitting multiple sclerosis (RRMS). The molecule is a sphingosine phosfate analog that because of its mechanism of action causes a decrease in heart rate during the administration of the first dosis and a slight increase in blood pressure in the second month of treatment in 0.5% of patients. We review in this article the cellular mechanisms by which fingolimod causes these events and report safety recommendations based on US Food and Drug Administration (FDA) for initiating treatment with this drug.

Palavras-chave : heart rate; pharmacology.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )